Wow a lot of concurrent news. If I am understanding, it appears that Immuron is 1) going an fda approval pathway for travelan, 2) gained more intellectual property rights for c diff treatment in the US, and 3) affirmed timely results release for their ASH trial (late q2) that just concluded. The travelan fda angle is smart, free marketing being the biggest benefit. Foreign travel is also still a lucrative business and their are niche travel medicine clinics that would easily adopt the usage of fda approved products without much pr expenditure needed. I’m not looking a gift horse in the mouth, but the timing of so many simultaneous updates appears to be a signal of some sort of news cycle/pathway beginning... I doubt this is the last we hear from them in the coming months, in addition to expected ASH results. Any type of positive signal generated by the ASH trial (ignoring their other free NIH trials ongoing in similar indications), could be very very well timed. It is a totally different mechanism than ICPT, (thank goodness, ICPT’s data and their pruritis/itching issues leave a lot to be desired)- so IMRN could in some ways fill a potential treatment void that ICPT’s lackluster results created. Ie if good, IMRN could demonstrate an anti inflammatory effect on liver that could then be tested in fibrosis pathways, possibly as a combo drug with some other compounds being tested for Nash, or to slow damage with alcoholics etc. Anyways, the super low mkt cap will likely lead me to add a bit more now. I’m most hopeful for c diff indication, and the travelan marketing fda pathway is just a bonus. The ash trial seems like biggest long shot, but also most immediate potential upside (landslide really) if it could hit. I’m investing for the c diff stuff, the ASH/NASH pathway is just a big lottery ticket. I bet a lot of people are looking for lottery tickets right now though, after the recent Nash failures in bigger companies. Best of luck all
